Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ticilimumab (CP-675,206) in advanced refractory or relapsed melanoma
2005-002826-70Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2005
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in melanoma, sponsored by Pfizer. Primary endpoint: Best Overall Response. Started Oct 2005; status: completed.
02
Drugs
tremelimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-002826-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002826-70.